Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials

Table 1 Participant characteristics of triptan insufficient responders (mITT Population)

BMI body mass index, CV cardiovascular, mITT modified intent-to-treat, SD standard deviation
^a ≥ 10% risk of CV disease within a 10-year period. CV disease risk assessed using an algorithm based on National Cholesterol Education Program (NCEP) risk factors and calculated Framingham Scores along with the presence of CV heart disease or other clinical forms of atherosclerotic disease, as well as diabetes

ISSN: 1129-2377